Apple's latest quarterly earnings reveal a tale of two halves: blockbuster iPhone sales, particularly in emerging markets like India, drove revenue to a new high, while Mac and wearables segments saw notable declines. The tech giant also faces questions over its AI strategy and conservative spending.
Investment bank Macquarie has raised its rating on NIO Inc. (NYSE:NIO) from Neutral to Outperform, citing better-than-expected fourth-quarter delivery figures and the growing success of its battery subscription model. The firm also increased its price target to $6.10.
KTM's preliminary 2025 financial results reveal a steep decline in revenue and sales, casting doubt on the efficacy of recent restructuring efforts and raising questions about the brand's near-term recovery trajectory.
PennyMac Financial Services reported Q4 2025 net income of $106.8 million, declaring a $0.30 per share dividend. While full-year profits grew on higher loan production, the quarter was pressured by a sharp decline in mortgage servicing income due to accelerated prepayments, highlighting the volatility inherent in its dual business model.
Nissan Motor Co. faced a 4.4% decline in global sales for 2025, with a sharper 6.7% drop in December, as weakness in key markets like China and Europe offset gains in North America.
While Legend Biotech's CAR-T therapy Carvykti missed Q4 sales estimates, prompting mixed analyst reactions, some firms emphasize its curative potential and view the stock's recent decline as a strategic entry point for investors.
While the sales and marketing software segment broadly exceeded revenue expectations in Q3, investor sentiment has turned sour, with most stocks falling post-earnings. We analyze the divergent performances of Upland Software, Sprinklr, DoubleVerify, PubMatic, and Sprout Social.
While investors chase AI and big tech, a niche biotech firm focused on rare genetic obesity disorders has quietly delivered staggering returns, with Wall Street seeing further 40% upside. Rhythm Pharmaceuticals' targeted approach and upcoming catalysts have analysts bullish, despite its relative anonymity.
Shares of Day One Biopharmaceuticals (NASDAQ: DAWN) have surged over 50% in the last three months, reigniting debate over its fair value and the risks tied to its lead drug OJEMDA and a pivotal upcoming data readout.
In a significant move to bolster its healthcare services and retain staff, Walmart is creating thousands of new leadership positions and raising wages for pharmacy technicians across its U.S. stores.
New market data reveals a stark generational divide in American drinking habits, with Gen Z contributing a mere 4% to total alcohol sales last year. The findings challenge long-held industry assumptions and highlight the enduring spending power of older consumers amid a broader shift toward premiumization and alternative beverages.
Amneal Pharmaceuticals' shares have surged over 64% in the past year, prompting investors to question if the rally still has room to run. A closer look at valuation metrics suggests the generic drugmaker may still be trading at a significant discount to its intrinsic value.
Industrial equipment maker Graco (NYSE: GGG) is expanding its powder technology footprint through the acquisition of Color Service, a specialist in gravimetric dosing. The move coincides with the company reporting record quarterly sales, fueled by organic growth and strategic integrations, signaling a period of focused expansion for the Minnesota-based firm.
A pair of aviator sunglasses worn by French President Emmanuel Macron during a high-profile moment at Davos has triggered a global sales frenzy for the historic brand Henry Jullien. While the Italian-owned company sees its stock and orders surge, industry veterans question whether the presidential spotlight can stem the long-term decline of French eyewear manufacturing.
Trimble expands its distribution network in key Midwestern markets by appointing West Side Tractor Sales Co. as a new authorized technology outlet and reseller, enhancing local access to its precision construction solutions for John Deere equipment users.
Tesla is discontinuing its flagship Model S sedan and Model X SUV, a strategic shift underscored by plummeting sales figures and Elon Musk's pivot toward robotics and autonomy.
Swiss watch and jewelry giant Swatch Group reported a steep decline in full-year profit and revenue, with pre-tax earnings nearly halved as consumer demand softened and operational costs climbed.
Robert Half International reports a pivotal return to sequential revenue growth in Q4 2025, signaling a potential turning point after a prolonged slump. However, the staffing giant continues to grapple with significant year-over-year declines, highlighting an uneven recovery path for the broader professional labor market.
PennyMac Mortgage Investment Trust (PMT) closed 2025 with robust earnings, driven by a dramatic expansion in its private-label securitization business. While this growth fueled returns, the company's correspondent lending segment faced pressure, and faster mortgage prepayments impacted servicing rights income.
PennyMac Financial Services capped a robust fiscal 2025 with Q4 net income of $107 million, overcoming headwinds from an unexpected wave of mortgage prepayments. While competitive pressures limited margin expansion, CEO David Spector pointed to strategic tech investments and a significant embedded refinance portfolio as catalysts for targeted mid-to-high teens ROE later this year.
